- Home
- JANX vs GRDN Comparison
JANX vs GRDN Comparison
Compare JANX & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- GRDN
- Stock Information
- Founded
- JANX 2017
- GRDN 2004
- Country
- JANX United States
- GRDN United States
- Employees
- JANX N/A
- GRDN N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- JANX Health Care
- GRDN Consumer Staples
- Exchange
- JANX Nasdaq
- GRDN Nasdaq
- Market Cap
- JANX 1.5B
- GRDN 1.3B
- IPO Year
- JANX 2021
- GRDN 2024
- Fundamental
- Price
- JANX $25.96
- GRDN $20.54
- Analyst Decision
- JANX Strong Buy
- GRDN Strong Buy
- Analyst Count
- JANX 8
- GRDN 2
- Target Price
- JANX $90.63
- GRDN $24.50
- AVG Volume (30 Days)
- JANX 839.1K
- GRDN 212.2K
- Earning Date
- JANX 08-06-2025
- GRDN 08-11-2025
- Dividend Yield
- JANX N/A
- GRDN N/A
- EPS Growth
- JANX N/A
- GRDN N/A
- EPS
- JANX N/A
- GRDN N/A
- Revenue
- JANX $9,336,000.00
- GRDN $1,282,307,000.00
- Revenue This Year
- JANX N/A
- GRDN $11.93
- Revenue Next Year
- JANX $1,470.82
- GRDN $2.18
- P/E Ratio
- JANX N/A
- GRDN N/A
- Revenue Growth
- JANX 28.12
- GRDN 19.55
- 52 Week Low
- JANX $22.48
- GRDN $14.16
- 52 Week High
- JANX $71.71
- GRDN $26.91
- Technical
- Relative Strength Index (RSI)
- JANX 53.36
- GRDN N/A
- Support Level
- JANX $25.81
- GRDN N/A
- Resistance Level
- JANX $27.31
- GRDN N/A
- Average True Range (ATR)
- JANX 1.30
- GRDN 0.00
- MACD
- JANX 0.08
- GRDN 0.00
- Stochastic Oscillator
- JANX 45.02
- GRDN 0.00
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.